Suppr超能文献

使用 RECIST 进行研究的数据捕获、验证和总结的建议。

Recommendations for capture, validation and summarisation of data from studies using RECIST.

机构信息

GlaxoSmithKline, Collegeville, PA 19426-0989, USA.

出版信息

Eur J Cancer. 2011 Mar;47(5):697-701. doi: 10.1016/j.ejca.2010.12.023.

Abstract

Response Evaluation Criteria in Solid Tumors (RECIST) is commonly used in oncology clinical trials and provides a standard approach for the assessment of treatment. However, data capture, validation and summarisation are complex. This article focuses on managing solid tumour lesion and response assessment data from capture through summarisation. Conventions for capturing lesion data, as well as considerations for data validation and summarisation, are provided. Recommendations are based on a review of data capture forms (including data items and instructions), data validation practices and algorithms for data summarisation across solid tumour studies at a single company. The intent of the authors is to share our experiences at GSK in the spirit of harmonisation by transparently describing our decisions and methods.

摘要

实体瘤反应评价标准(RECIST)常用于肿瘤学临床试验,为治疗评估提供了一种标准方法。然而,数据的采集、验证和总结非常复杂。本文重点关注从数据采集到总结的实体瘤病灶和反应评估数据的管理。本文提供了病灶数据采集的规范,以及数据验证和总结的注意事项。这些建议是基于对单个公司的实体瘤研究中数据采集表(包括数据项和说明)、数据验证实践以及数据总结算法的回顾。作者旨在通过透明地描述决策和方法,本着协调一致的精神,分享他们在葛兰素史克公司的经验。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验